Abivax Stock Soars 31% on Positive Ulcerative Colitis Drug Data

Shares of French biotech company Abivax surged by 31% after the release of new positive Phase 3 data for its experimental medicine targeting ulcerative colitis. The promising results have led to a significant jump in the company's stock.